A practical reference on GHRH analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
The 2026 FIFA World Cup was the 23rd FIFA World Cup, the quadrennial international men's soccer championship contested by the national teams of the member associations of FIFA. The tournament began on June 11, 2026, and concluded on July 19 with Spain winning the championship for the second time. It was jointly hosted by 16 cities—11 in the United States, 3 in Mexico, and 2 in Canada. The tournament was the first FIFA World Cup to be hosted by three countries and the first to include 48 teams, an expansion from the previous 32-team format. The 2026 tournament was the second World Cup to be hosted by multiple nations, after the 2002 edition. Mexico became the first country to host the World Cup three times, having hosted the 1970 and 1986 tournaments. The United States previously hosted the World Cup in 1994, while it was Canada's first time hosting the tournament. The event returned to its traditional June–July schedule after the 2022 World Cup in Qatar, which was uniquely held in November and December to avoid Qatar's extreme summer heat. Canada, Mexico, and the United States qualified automatically as hosts, while Cape Verde, Curaçao, Jordan, and Uzbekistan made their World Cup debuts. For the first time in the tournament's history, the top four teams from the FIFA Men's World Ranking at the time of the contest (Argentina, Spain, France, and England) advanced to the semifinals. Spain won the final against defending champion Argentina 1–0 after extra time, winning its second title and first since 2010.
== R == radioisotope - radioisotopic labelling - Raman spectroscopy - random coil - Ras gene - Ras protein - reading frame - receptor (biochemistry) - receptor antagonist - receptor protein-tyrosine kinase - recombinant fusion protein - recombinant interferon-gamma - recombinant protein - recombination - redox - redox reaction - redox system - reflux - replication origin - replicon - repressor - repressor protein - respiration (physiology) - restriction enzyme - retinoblastoma protein - retinoic acid receptor - retinol-binding protein - retroelement - retroviridae protein - retrovirus - Reverse transcriptase - RFLP - rho factor - rhodopsin - ribonucleoprotein - ribose - ribosomal protein - ribosomal protein S6 kinase - ribosome - RNA - RNA virus - RNA-binding protein - RNA-directed DNA polymerase - rod outer segment - rough ER
==== 118A>G variant ==== While over 100 variants have been identified for the opioid mu-receptor, the most studied mu-receptor variant is the non-synonymous 118A>G variant, which results in functional changes to the receptor, including lower binding site availability, reduced mRNA levels, altered signal transduction, and increased affinity for beta-endorphin. In theory, all these functional changes would reduce the impact of exogenous opioids, requiring a higher dose to achieve the same therapeutic effect. This points to a potential for greater addictive capacity in individuals who require higher dosages to achieve pain control. Evidence linking the 118A>G variant to opioid dependence is mixed, with associations shown in some study groups but negative results in other groups. One explanation for the mixed results is the possibility of other variants that are in linkage disequilibrium with the 118A>G variant and thus contribute to different haplotype patterns more specifically associated with opioid dependence.
== Inhibition == The main inhibitor of tissue plasminogen activator and urokinase is plasminogen activator inhibitor-1 (PAI-1). Plasminogen activator inhibitor-1 is a serine protease, synthesized by endothelial cells, that specifically inhibits tissue plasminogen activator (tPA) and urokinase (uPA). Tissue plasminogen activator and urokinase are the activators of plasminogen and result in the breakdown of blood clots (fibrinolysis). PAI-1 levels have also been studied in patients and how they influence certain diseases. Elevated serum levels of PAI-1 have been found in obese individuals. Elevated levels of PAI-1 also seem to increase the risk of atherothrombotic events and may also promote vascular disease. Plasminogen activator inhibitor-2 (PAI-2) is a serine protease that inactivates tPA and uPA. PAI-2 is produced by the placenta and only found in high quantities in the blood during pregnancy.
Sources: en.wikipedia.org
While the main habitat of earthworms is in soil, they are not restricted to this habitat. The brandling worm Eisenia fetida lives in decaying plant matter and manure. Arctiostrotus vancouverensis from Vancouver Island and the Olympic Peninsula is generally found in decaying conifer logs. Aporrectodea limicola, Sparganophilus spp., and several others are found in mud in streams (riparian species). Some species are arboreal, some aquatic and some euryhaline (salt-water tolerant) and littoral (living on the sea-shore), e.g. Pontodrilus litoralis. Even in the soil species, special habitats, such as ultramafic soils derived from serpentine, have an earthworm fauna of their own, e.g. New Caledonian Acanthodrilidae. Vermicomposting of organic wastes is currently processed using the epigeic Eisenia fetida and Eisenia andrei which are particularly adapted to the consumption of fresh organic matter without deepening in the substrate (contrary to the anecis Lumbricus terrestris) and which tolerate the heat generated in compost heaps. Addition of this humified organic matter to the soil, preferably as a surface mulch, will improve moisture and nutrient availability, with beneficial effects on the soil microflora. It will also provide several species of earthworms with their food and nutrient requirements, and will create the optimum conditions of temperature and moisture that will stimulate their activity, although to a lesser extent than bacterial-mediated compost. Earthworms are environmental indicators of soil health.
== Terminology == A supply involves the procurement, distribution, maintenance while in storage, and salvage of supplies, including the determination of kind and quantity of supplies. United States Department of Defense definitions refer to a "producer phase" and a "consumer phase":
Globally, as of 2010, approximately 250 million people had osteoarthritis of the knee (3.6% of the population). Hip osteoarthritis affects about 0.85% of the population. As of 2004, osteoarthritis globally causes moderate to severe disability in 43.4 million people. Together, knee and hip osteoarthritis had a ranking for disability globally of 11th among 291 disease conditions assessed.
Given that the version of the theory we are testing is universalistic in its claims – that 'hegemony leads to balance … through all of the centuries we can contemplate' – case selection is unimportant. Any significant counterexample falsifies the universal claim; eight such examples demolish it. Wohlforth et al. state that systemic hegemony is likely under two historically common conditions: First when the rising hegemon develops the ability to incorporate and effectively administer conquered territories. And second, when the boundaries of the international system remain stable, and no new major powers emerge from outside the system. When the leading power can administer conquests effectively so they add to its power and when the system's borders are rigid, the probability of hegemony is high. The argument of universal reproduction of anarchy can be correct in the European context, "whereas a systematic survey of world history reveals that multipolarity has frequently given way to unipolarity or hegemony." Henry Kissinger, historian by profession, noted that "theories of the balance of power often leave the impression that it is the natural form of international relations. In fact, balance-of-power systems have existed only rarely in history." Yet based on these rare occurrences, many realists "elevate a fact of life … into a guiding principle of world order." Earlier, political scientist Martin Wight had drawn a conclusion with unambiguous implication for the modern world:
Self-amplifying mRNA (saRNA) vaccines replicate their mRNA after transfection. Self-amplifying mRNA has two open reading frames. The first frame, like conventional mRNA, codes for the antigen of interest. The second frame codes for an RNA-dependent RNA polymerase (and its helper proteins) which replicates the mRNA construct in the cell. This allows smaller vaccine doses. The mechanisms and consequently the evaluation of self-amplifying mRNA may be different, as self-amplifying mRNA is a much bigger molecule. SaRNA vaccines being researched include a malaria vaccine. The first saRNA Covid vaccine authorised was Gemcovac, in India in June 2022. The second was ARCT-154, developed by Arcturus Therapeutics. A version manufactured by Meiji Seika Pharma was authorised in Japan in November 2023. GSK began a phase 1 trial of an saRNA COVID-19 vaccine in 2021. Gritstone bio started also started a phase 1 trial of an saRNA COVID-19 vaccine in 2021, used as a booster vaccine, with interim results published in 2023. The vaccine is designed to target both the spike protein of the SARS‑CoV‑2 virus, and viral proteins that may be less prone to genetic variation, to provide greater protection against SARS‑CoV‑2 variants. saRNA vaccines must use uridine, which is required for reproduction to occur.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It is a laboratory-made peptide that mimics growth hormone-releasing hormone. It prompts the pituitary gland to release growth hormone and has been studied mainly in adults with HIV-associated lipodystrophy.